paroxetine has been researched along with cyclohexanol in 182 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 30 (16.48) | 18.2507 |
| 2000's | 112 (61.54) | 29.6817 |
| 2010's | 39 (21.43) | 24.3611 |
| 2020's | 1 (0.55) | 2.80 |
| Authors | Studies |
|---|---|
| Perez, J; Popoli, M; Racagni, G; Smeraldi, E; Vocaturo, C | 1 |
| Preskorn, SH | 2 |
| Jaffe, IA | 1 |
| Althof, SE | 1 |
| Castañeda, R; Levy, R; Sussman, N; Westreich, LM | 1 |
| Gartside, SE; Sharp, T; Umbers, V | 1 |
| Ahern, D; Ball, SE; Kao, J; Scatina, J | 1 |
| Adès, J; Lejoyeux, M | 1 |
| Haddad, P | 1 |
| Meynaar, IA; Mulder, AH; Ottervanger, JP; Peeters, AJ | 1 |
| Mitchell, S; Tracy, KA; Zajecka, J | 1 |
| Richelson, E | 1 |
| Bagby, RM; Dickens, SE; Joffe, R; Kennedy, SH; Levitt, A; Minifie, CE; Schuller, DR | 1 |
| Gorman, JM | 3 |
| Amsterdam, JD; Garcia-España, F; Goodman, D; Hooper, M; Hornig-Rohan, M | 1 |
| Clement, EM; Franklin, M; Odontiadis, J | 1 |
| Béïque, JC; Blier, P; de Montigny, C; Debonnel, G | 4 |
| Anand, VS; Dewan, MJ | 1 |
| Bitsios, P; Bradshaw, CM; Szabadi, E | 1 |
| Boyer, P | 1 |
| Poirier, MF | 1 |
| Abdelmawla, AH; Bradshaw, CM; Langley, RW; Szabadi, E | 1 |
| McAllister-Williams, RH; Porter, RJ; Young, AH | 1 |
| Connor, TJ; Kelly, JP; Leonard, BE; Nolan, Y; Shen, Y | 1 |
| Boyer, P; Poirier, MF | 1 |
| Alfaro, CL; Ereshefsky, L; Lam, YW; Simpson, J | 1 |
| Anisman, H; Griffiths, J; Merali, Z; Ravindran, AV; Zaharia, MD | 1 |
| Connor, TJ; Harkin, A; Kelliher, P; Kelly, JP; Leonard, BE; Shen, Y | 1 |
| Farmer, AE; Malhi, GS | 1 |
| Gregson, J | 1 |
| Dunn, NR; Freemantle, SN; Mackay, FR; Mann, RD; Martin, RM; Pearce, GL | 1 |
| Daniels, S | 1 |
| Bacchiochi, JR; Bagby, RM; Dickens, SE; Eisfeld, BS; Kennedy, SH | 1 |
| Ballús, C; Casais, L; De Flores, T; de la Torre, J; Gutiérrez, M; Palao, D; Quiros, G; Riesgo, Y; Rojo, L | 1 |
| MacIver, DH; Partridge, SJ; Solanki, T | 1 |
| Deslandes, PN; Pache, DM; Sewell, RD; Subhan, F | 1 |
| Caputo, RM; Stern, S; Votolato, NA | 1 |
| Fitzgerald, F; Glod, CA; Lynch, A | 1 |
| Cook, IA; Leuchter, AF | 1 |
| Devarajan, S; Dursun, SM; Haddad, PM | 1 |
| Perry, CM; Wellington, K | 1 |
| Boskailo, E; Djuric-Bijedic, Z; Lewis, J; Pavkovic, I; Smajkic, A; Weine, S | 1 |
| Boskailo, E; Durić-Bijedić, Z; Lewis, J; Pavković, I; Smajkić, A; Weine, S | 1 |
| Bagby, RM; Kennedy, SH; Vanderkooy, JD | 1 |
| Baker, GB; Kennedy, SH; Masellis, M; McCann, SM; McIntyre, RS; McKay, G; Raskin, J | 1 |
| Ismail, M; Lyster, G | 1 |
| Culpepper, L | 1 |
| Benabarre, A; Colom, F; Goikolea, JM; Martinez-Arán, A; Reinares, M; Torrent, C; Vieta, E | 1 |
| Denys, D; van Megen, H; Westenberg, H | 1 |
| Benkert, O; Muller, M; Szegedi, A | 1 |
| Entsuah, R; Rudolph, RL; Stahl, SM | 1 |
| Burton, D; Camilleri, M; Chial, HJ; Olden, KW; Stephens, D; Thomforde, G | 1 |
| Denys, DA; Glas, G; Tenney, NH; van Megen, HJ; Westenberg, HG | 1 |
| Thase, ME; Trivedi, M | 1 |
| Beyer, CE; Boikess, S; Dawson, LA; Luo, B | 1 |
| Rickels, K; Rynn, M | 1 |
| Bourin, M; David, DJ; Gardier, AM; Jego, G; Jolliet, P; Przybylski, C | 1 |
| Grauer, MT; Holsboer, F; Uhr, M | 1 |
| Burger, H; de Geus, F; Denys, D; van Megen, H; Westenberg, H | 1 |
| Pei, Q; Sharp, T; Sprakes, M; Tordera, R; Zetterström, TS | 1 |
| Borgeat, F; Hättenschwiler, J; Khazaal, Y; Mattia, M; Stankovic, M; Zullino, DF | 1 |
| Denys, D; van der Wee, N; van Megen, HJ; Westenberg, HG | 2 |
| Goetz, MP; Loprinzi, CL | 1 |
| DeVane, CL | 1 |
| Nemeroff, CB | 1 |
| Hwang, JP; Tsai, SJ; Yang, CH | 1 |
| Angulo, J; Cuevas, B; Cuevas, P; Gupta, S; Sáenz de Tejada, I | 1 |
| Bateman, DN; Chick, J; Good, AM; Kelly, CA; Masterton, G | 1 |
| Carella, A; Cheok, A; Ginovart, N; Houle, S; Hussey, D; Meyer, JH; Potter, WZ; Sagrati, S; Spencer, EP; Wilson, AA | 1 |
| Stearns, V | 1 |
| Hemrick-Luecke, SK; Iyengar, S; Simmons, RM; Webster, AA; Xu, JY | 1 |
| Andrews, G; Carter, R; Donnelly, M; Haby, MM; Heuzenroeder, L; Mihalopoulos, C; Rossell, R; Vos, T | 1 |
| Allgulander, C; Dahl, AA; Emilien, G; Lepola, U; Mangano, R; Sjödin, I; Zhang, J | 1 |
| Casciano, R; Chen, J; Geissler, EC; Mallick, R; Panish, JM; Trivedi, MH; Wan, GJ | 1 |
| Basinski, J; Begley, A; Dew, MA; Farhi, P; Mulsant, BH; Reynolds, CF; Whyte, EM | 1 |
| Gelenberg, AJ; Liebowitz, MR; Munjack, D | 1 |
| Bloch, DA; Ciraulo, AM; Ciraulo, DA; Elkashef, A; Knapp, CM; Leiderman, DB; LoCastro, J; Montgomery, MA; Sarid-Segal, O | 1 |
| Addington, S; Dichter, GS; Freid, CM; Shelton, RC; Tomarken, AJ | 1 |
| Bourin, M; Clénet, F; Hascoët, M; Nic Dhonnchadha, BA; Ripoll, N | 1 |
| Huande, L; Juan, H; Zhiling, Z | 1 |
| Cunha, A; Gazalle, FK; Kapczinski, F; Lima, MS; Schmitt, R; Souza, J | 1 |
| Bourin, M; Hascoët, M; Nic Dhonnchadha, BA; Ripoll, N; Sébille, V | 1 |
| Entsuah, R; Padmanabhan, SK; Shelton, C; Vinall, PE | 1 |
| Bourin, M; Hascoët, M; Massé, F | 1 |
| Altamirano, AV; Frazer, A; Gould, GG; Javors, MA | 1 |
| Carpenter, D; Connor, K; Davidson, J; Krishnan, R; Krulewicz, S; Nemeroff, C; Owens, M; Watkins, L | 1 |
| Denys, DA; Tenneij, NH; van Megen, HJ; Westenberg, HG | 1 |
| Denys, D; Fluitman, S; Heijnen, C; Kavelaars, A; Westenberg, HG | 1 |
| Fava, M; Mallinckrodt, CH; Martinez, JM; Prakash, A; Watkin, JG; Wohlreich, MM | 1 |
| Baldwin, DS; Lader, M; Montgomery, SA; Nil, R | 1 |
| Lang, AE; Voon, V | 1 |
| Albertazzi, P | 1 |
| Dervaux, A | 1 |
| Blier, P; de Montigny, C; Debonnel, G; Hébert, C; Lavoie, N; Saint-André, E | 1 |
| Bahk, WM; Chae, JH; Jun, TY; Kim, TS; Pae, CU; Rhee, WI; Yoon, SJ | 1 |
| Kim, YK; Lee, KM | 1 |
| Connolly, A; Stewart, S; Taylor, D | 1 |
| Emilien, G; Gao, B; Koponen, H; Lepola, U; Pollack, MH; Salinas, E; Simon, NM; Tzanis, E; Whitaker, T; Worthington, JJ | 1 |
| Krol, DG; Nolen, WA | 1 |
| Corral, M; Kendrick, K; Misri, S; Wardrop, AA | 1 |
| Eastwood, BJ; Jones, CK; Need, AB; Shannon, HE | 1 |
| Conti, M; Frasnelli, M; Rosetti, M; Tesei, A; Zoli, W | 1 |
| Colombo, C; De Ronchi, D; Mandelli, L; Rossini, D; Serretti, A; Tarricone, I; Zanardi, R | 1 |
| Connor, K; Davidson, JR; Vaishnavi, S | 1 |
| Deforce, D; Denys, D; Van Nieuwerburgh, F; Westenberg, HG | 1 |
| Heerdink, ER; van Dijk, L; Volkers, AC | 1 |
| Entsuah, R; Mangano, R; Pollack, M; Simon, NM; Tzanis, E; Zhang, Y | 1 |
| Chen, YC; Lu, RB; Wu, YS | 1 |
| Benattia, I; Demitrack, M; Entsuah, R; Nemeroff, CB; Sloan, DM; Thase, ME | 1 |
| Aviv, A; Barak, Y; Mazeh, D; Shahal, B; Zemishlani, H | 1 |
| Busto, G; Di Spigno, D; Falcini, R; Salvati, L; Tundo, A | 1 |
| Borah, M; Radhakrishnan, M; Ramamoorthy, R | 1 |
| de Pisa, E; Girardi, P; Kotzalidis, GD; Patrizi, B; Ruberto, G; Savoja, V | 1 |
| Abebe, K; Asarnow, JR; Birmaher, B; Brent, D; Clarke, G; DeBar, L; Emslie, G; Hughes, C; Iyengar, S; Keller, M; Kennard, B; Leonard, H; McCracken, J; Melhem, N; Onorato, M; Porta, G; Ritz, L; Ryan, N; Spirito, A; Strober, M; Suddath, R; Vitiello, B; Wagner, KD; Zelazny, J | 1 |
| Berman, RM; Carson, WH; Fava, M; Hennicken, D; Marcus, RN; McQuade, RD; Simon, JS; Thase, ME; Trivedi, MH | 1 |
| Carpenter, DJ; Krulewicz, S; Nemeroff, CB; Owens, MJ; Plott, SJ; Sheehan, DV; Simon, JS; Thase, ME | 1 |
| Kelly, BD | 1 |
| Kim, YK; Lee, HY | 1 |
| Ahmed, S; Fatato, P; Isler, JA; Jiang, Q; Nichols, AI; Patroneva, A; Paul, J; Pedersen, RD; Shenouda, M | 1 |
| Guico-Pabia, CJ; Helzner, EC; Nichols, AI; Patroneva, AL; Paul, J; Preskorn, SH | 1 |
| Asarnow, JR; Birmaher, B; Brent, D; Clarke, G; DeBar, L; Emslie, G; Iyengar, S; Keller, M; Kennard, B; Leonard, H; Mayes, T; McCracken, J; Porta, G; Ritz, L; Ryan, N; Shamseddeen, W; Spirito, A; Strober, M; Suddath, R; Vitiello, B; Wagner, KD | 1 |
| Asarnow, J; Birmaher, B; Brent, DA; Clarke, GN; Debar, LL; Emslie, GJ; Iyengar, S; Keller, MB; Kennard, B; Leonard, H; Mayes, TL; McCracken, JT; Onorato, M; Porta, G; Ritz, L; Ryan, ND; Spirito, A; Strober, M; Suddath, R; Vitiello, B; Zelazny, J | 1 |
| Sanderson, K | 1 |
| Andersohn, F; Garbe, E; Schade, R; Suissa, S | 1 |
| Spadone, C | 1 |
| Smith, E | 1 |
| Benedet, J; Carvalho-Silva, M; Jeremias, GC; Quevedo, J; Rezin, GT; Rochi, N; Santos, PM; Scaini, G; Streck, EL | 1 |
| Brent, DA | 1 |
| Boerner, RJ | 1 |
| Howland, RH | 1 |
| Drummer, OH; Gerostamoulos, D; Pilgrim, JL | 1 |
| Brophy, JM; Etminan, M; Mikelberg, FS | 1 |
| Benedet, J; Borges, LS; Gomes, LM; Pezente, DP; Quevedo, J; Rezin, GT; Rochi, N; Santos, PM; Scaini, G; Streck, EL | 1 |
| Bérard, A; Broy, P; Nakhai-Pour, HR | 1 |
| Cao, L; Chen, J; Cui, X; Fang, Y; Gao, K; Hong, W; Jiang, K; Nierenberg, AA; Wang, Y; Wu, Z; Xu, Y; Yi, Z; Yuan, C | 1 |
| Deshpande, A; Ing, A; Rizo, C; Seeman, N | 1 |
| Kourti, PV; Samanidou, VF | 1 |
| Aubry, JM; Bertschy, G; Bondolfi, G; Gex-Fabry, M; Kosel, M; Malafosse, A; Perroud, N; Uher, R | 1 |
| Corbeil, P; McDonald, J; Pourcher, E | 1 |
| Beste, J; Blackwell, JC; Patel, BN | 1 |
| Cassano, GB; Mula, M; Pini, S; Preve, M | 1 |
| Cuestas, E; Cuestas, ME | 1 |
| Alexander, R; Archer, G; Evoniuk, G; Graff, O; Krishnan, KR; Lavergne, A; Learned, S; Moate, R; Modell, JG; Ratti, E; Roychowdhury, S; Zamuner, S | 1 |
| Lee, KU; Lee, YM | 1 |
| Asarnow, JR; Birmaher, B; Brent, DA; Clarke, G; Emslie, GJ; Keller, MB; Porta, G; Ryan, N; Shamseddeen, W; Wagner, KD | 1 |
| Knapp, LE; Miceli, JJ; Ramey, TS; Rickels, K; Shiovitz, TM; Weaver, JJ | 1 |
| Dahmen, N; Engel, A; Gerbaulet, M; Hiemke, C | 1 |
| Friedman, JH; Weintraub, D | 1 |
| Black, KJ; Brodsky, M; Christine, CW; Como, PG; Elmer, L; Factor, SA; Fernandez, HH; Horn, S; Hyson, HC; Jiang, W; Juncos, J; Kurlan, R; Lyness, JM; Manning, C; Marsh, L; McDermott, MP; McDonald, W; Panisset, M; Pearson, N; Pfeiffer, R; Press, D; Richard, IH; Rottenberg, D; Serrano Ramos, C; Shulman, L; Singer, C; Slevin, J | 1 |
| Kovatsi, L; Livanos, A; Njau, S; Pantazidou, K; Samanidou, V | 1 |
| Barbui, C; Churchill, R; Cipriani, A; Furukawa, TA; Imperadore, G; Purgato, M; Signoretti, A; Trespidi, C; Watanabe, N | 1 |
| Holsboer, F; Perisic, T; Rein, T; Yu, S; Zimmermann, N; Zschocke, J | 1 |
| Barbui, C; Cipriani, A; Furukawa, TA; Koesters, M; Nosè, M; Omori, IM; Purgato, M; Trespidi, C | 1 |
| Humpston, CS; Robinson, ES; Wood, CM | 1 |
| Blum, WF; Colla, M; Daseking, E; Deuschle, M; Gilles, M; Heuser, I; Kopf, D; Krumm, B; Lederbogen, F; Schilling, C; Weber-Hamann, B; Wudy, SA | 1 |
| Li, L; Lin, M; Qian, MC; Shen, XH; Sun, JS; Yang, JH; Zhang, J; Zhong, H | 1 |
| Cao, L; Chen, J; Fang, Y; Hong, W; Peng, D; Wu, Z; Yuan, C; Zhang, C | 1 |
| Asarnow, JR; Birmaher, B; Brent, DA; Clarke, GN; Emslie, GJ; He, J; Hilton, RC; Keller, MB; Mansoor, B; Mayes, T; Porta, G; Rengasamy, M; Ryan, N; Shamseddeen, W; Wagner, KD | 1 |
| Berk, M; Dodd, S; Kelin, K; Mancini, M; Schacht, A | 1 |
| Filov, I; Gerazova, VP; Marinov, P; Novotni, A; Ristevska-Dimitrovska, G; Shishkov, R; Stefanovski, B; Vujovik, V | 1 |
| Birmaher, B; Brent, D; Clarke, G; Emslie, GJ; He, J; Hilton, R; Mansoor, B; Mayes, TL; Porta, G; Rengasamy, M; Ryan, N; Shamseddeen, W; Spirito, A; Wagner, KD | 1 |
| Bijlsma, EY; Chan, JS; Millan, MJ; Olivier, B; Oosting, RS; Veening, JG; Waldinger, MD | 1 |
| Groot, PC | 1 |
| de Bodinat, C; Lejoyeux, M; Matharan, S | 1 |
| Alberti, S; Chiesa, A; Han, C; Lee, SJ; Lia, L; Pae, CU; Patkar, AA; Serretti, A | 1 |
| Auinger, P; Christine, CW; Factor, SA; Juncos, J; Leentjens, AF; Lyness, JM; Marsh, L; McDonald, W; Moonen, AJ; Panisset, M; Pfeiffer, R; Richard, IH; Rottenberg, D; Serrano Ramos, C; Shulman, L; Singer, C; Slevin, J; Wijers, A | 1 |
| Chang, YH; Chen, PS; Chen, SH; Chen, SL; Cheng, LY; Chu, CH; Chuang, HY; Lee, IH; Lu, RB; Wang, YS; Yang, YK; Yeh, TL | 1 |
| Davis, ML; Hofmann, SG; Smits, JA | 1 |
| Banzi, R; Cusi, C; Moja, L; Randazzo, C; Sterzi, R; Tedesco, D | 1 |
| Aldosary, F; Blier, P; James, JS; Norris, S; Ritchie, JC; Tremblay, P | 1 |
35 review(s) available for paroxetine and cyclohexanol
| Article | Year |
|---|---|
Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine.
Topics: 1-Naphthylamine; Antidepressive Agents; Bupropion; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder; Drug Design; Drug Tolerance; Drugs, Investigational; Fluoxetine; Humans; Imipramine; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Sertraline; Triazoles; Venlafaxine Hydrochloride | 1995 |
Pharmacologic treatment of rapid ejaculation.
Topics: 1-Naphthylamine; Adult; Clinical Trials as Topic; Clomipramine; Cyclohexanols; Dose-Response Relationship, Drug; Ejaculation; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Psychotropic Drugs; Selective Serotonin Reuptake Inhibitors; Sertraline; Sexual Dysfunctions, Psychological; Venlafaxine Hydrochloride | 1995 |
Antidepressant discontinuation: a review of the literature.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Cyclohexanols; Depressive Disorder; Fluoxetine; Humans; Incidence; Monoamine Oxidase Inhibitors; Paroxetine; Recurrence; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome; Syndrome; Venlafaxine Hydrochloride | 1997 |
Newer antidepressants and the discontinuation syndrome.
Topics: Adverse Drug Reaction Reporting Systems; Cyclohexanols; Dizziness; Fluoxetine; Headache; Humans; Incidence; Nausea; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sleep Stages; Substance Withdrawal Syndrome; Syndrome; Venlafaxine Hydrochloride | 1997 |
Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review.
Topics: 1-Naphthylamine; Adolescent; Adult; Child; Clinical Trials as Topic; Cyclohexanols; Dizziness; Female; Fluoxetine; Fluvoxamine; Headache; Humans; Infant; Infant, Newborn; Male; MEDLINE; Mental Disorders; Middle Aged; Nausea; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sensation Disorders; Sertraline; Sleep Initiation and Maintenance Disorders; Substance Withdrawal Syndrome; Venlafaxine Hydrochloride | 1997 |
Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs.
Topics: 1-Naphthylamine; Antidepressive Agents; Cyclohexanols; Cytochrome P-450 Enzyme System; Drug Interactions; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Venlafaxine Hydrochloride | 1997 |
The use of newer antidepressants for panic disorder.
Topics: 1-Naphthylamine; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Benzodiazepines; Clinical Trials as Topic; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Fluoxetine; Fluvoxamine; Humans; Monoamine Oxidase Inhibitors; Panic Disorder; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 1997 |
Psychopharmacologic treatment of adolescent depression.
Topics: Adolescent; Child; Cyclohexanols; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Venlafaxine Hydrochloride | 2001 |
Venlafaxine extended-release: a review of its use in the management of major depression.
Topics: Antidepressive Agents, Second-Generation; Anxiety; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Drug Interactions; Fluoxetine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2001 |
Treatment of generalized anxiety disorder.
Topics: Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Agents, Tricyclic; Anxiety Disorders; Benzodiazepines; Buspirone; Clinical Trials as Topic; Cognitive Behavioral Therapy; Cyclohexanols; Follow-Up Studies; Humans; Paroxetine; Psychotherapy; Pyrimidines; Relaxation Therapy; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2002 |
Generalized anxiety disorder in primary care: emerging issues in management and treatment.
Topics: Adaptation, Psychological; Adolescent; Adult; Anxiety Disorders; Cognitive Behavioral Therapy; Comorbidity; Cyclohexanols; Depressive Disorder; Female; Humans; Male; Middle Aged; Paroxetine; Physicians, Family; Prevalence; Primary Health Care; Recurrence; Selective Serotonin Reuptake Inhibitors; Sleep Initiation and Maintenance Disorders; United States; Venlafaxine Hydrochloride | 2002 |
An overview of the clinical efficacy of mirtazapine.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder; Humans; Mianserin; Mirtazapine; Paroxetine; Selective Serotonin Reuptake Inhibitors; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2002 |
Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Fluvoxamine; Humans; Male; Paroxetine; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Time Factors; Venlafaxine Hydrochloride | 2002 |
Optimizing treatment outcomes for patients with depression and generalized anxiety disorder.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Cyclohexanols; Depressive Disorder, Major; Humans; Paroxetine; Psychotherapy; Randomized Controlled Trials as Topic; Remission Induction; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2002 |
Pharmacotherapy of generalized anxiety disorder.
Topics: Algorithms; Alprazolam; Antidepressive Agents; Antidepressive Agents, Tricyclic; Anxiety Disorders; Benzodiazepines; Buspirone; Combined Modality Therapy; Cyclohexanols; Delayed-Action Preparations; Drug Administration Schedule; Humans; Paroxetine; Psychotherapeutic Processes; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 2002 |
Treating generalized anxiety disorder.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Anxiety Disorders; Benzodiazepines; Buspirone; Clinical Trials as Topic; Cognitive Behavioral Therapy; Cyclohexanols; Humans; Imipramine; Paroxetine; Psychotherapy; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; United States; Venlafaxine Hydrochloride | 2003 |
[Pharmacotherapy of generalized anxiety disorder: state of the art].
Topics: Adolescent; Adult; Age Factors; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety Disorders; Benzodiazepines; Child; Child, Preschool; Cyclohexanols; Double-Blind Method; Humans; Meta-Analysis as Topic; Paroxetine; Placebos; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sleep Initiation and Maintenance Disorders; Time Factors; Venlafaxine Hydrochloride | 2003 |
A hot flash on tamoxifen metabolism.
Topics: Antidepressive Agents, Second-Generation; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cyclohexanols; Cytochrome P-450 CYP2D6; Estrogen Receptor Modulators; Estrogen Replacement Therapy; Female; Fluoxetine; Hot Flashes; Humans; Hydroxylation; Paroxetine; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Venlafaxine Hydrochloride | 2003 |
Immediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea.
Topics: Antidepressive Agents; Bupropion; Cyclohexanols; Delayed-Action Preparations; Drug Tolerance; Half-Life; Humans; Nausea; Paroxetine; Randomized Controlled Trials as Topic; Venlafaxine Hydrochloride | 2003 |
Improving antidepressant adherence.
Topics: Antidepressive Agents; Bupropion; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder; Health Promotion; Humans; Paroxetine; Patient Compliance; Randomized Controlled Trials as Topic; Venlafaxine Hydrochloride | 2003 |
Management of hot flashes in breast cancer survivors and men with prostate cancer.
Topics: Amines; Anti-Anxiety Agents; Breast Neoplasms; Complementary Therapies; Contraceptives, Oral, Synthetic; Cyclohexanecarboxylic Acids; Cyclohexanols; Drug Therapy, Combination; Estrogen Replacement Therapy; Female; Gabapentin; gamma-Aminobutyric Acid; Hot Flashes; Humans; Male; Medroxyprogesterone; Menopause, Premature; Paroxetine; Prostatic Neoplasms; Quality of Life; Selective Serotonin Reuptake Inhibitors; Survivors; Treatment Outcome; Venlafaxine Hydrochloride | 2004 |
Cost-effectiveness of psychological and pharmacological interventions for generalized anxiety disorder and panic disorder.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Australia; Cost-Benefit Analysis; Cyclohexanols; Disability Evaluation; Humans; Imipramine; Mental Health Services; Panic Disorder; Paroxetine; Psychotherapy; Selective Serotonin Reuptake Inhibitors; Time Factors; Venlafaxine Hydrochloride | 2004 |
The efficacy of antidepressants for generalized anxiety disorder: a systematic review and meta-analysis.
Topics: Antidepressive Agents; Anxiety Disorders; Cyclohexanols; Female; Humans; Imipramine; Male; Paroxetine; Randomized Controlled Trials as Topic; Treatment Outcome; Venlafaxine Hydrochloride | 2005 |
Discontinuation symptoms in depression and anxiety disorders.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Cyclohexanols; Depressive Disorder, Major; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Paroxetine; Substance Withdrawal Syndrome; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride; Withholding Treatment | 2007 |
Noradrenergic and serotonergic modulation to treat vasomotor symptoms.
Topics: Citalopram; Cyclohexanols; Female; Fluoxetine; Hot Flashes; Humans; Menopause; Mianserin; Mirtazapine; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Trazodone; Venlafaxine Hydrochloride | 2006 |
Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Citalopram; Cyclohexanols; Depressive Disorder, Major; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Randomized Controlled Trials as Topic; Remission Induction; Selective Serotonin Reuptake Inhibitors; Sertraline; Venlafaxine Hydrochloride | 2008 |
Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Cyclohexanols; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Desipramine; Desvenlafaxine Succinate; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Health Status; Humans; Paroxetine; Thiophenes | 2008 |
[Severe forms of depression: the efficacy of escitalopram].
Topics: Antidepressive Agents, Second-Generation; Citalopram; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Follow-Up Studies; Humans; Paroxetine; Personality Inventory; Psychometrics; Thiophenes; Treatment Outcome; Venlafaxine Hydrochloride | 2009 |
[Anxiety disorders: diagnosis and therapy from the family physician's perspective].
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Anxiety Disorders; Behavior Therapy; Cognitive Behavioral Therapy; Cyclohexanols; Diagnosis, Differential; Family Practice; Humans; Panic Disorder; Paroxetine; Practice Guidelines as Topic; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2006 |
Citalopram versus other anti-depressive agents for depression.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Depression; Humans; Morpholines; Paroxetine; Reboxetine; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2012 |
Duloxetine versus other anti-depressive agents for depression.
Topics: Antidepressive Agents; Citalopram; Cyclohexanols; Depression; Desvenlafaxine Succinate; Dibenzothiazepines; Duloxetine Hydrochloride; Fluoxetine; Humans; Paroxetine; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Thiophenes; Venlafaxine Hydrochloride | 2012 |
Treatment response for acute depression is not associated with number of previous episodes: lack of evidence for a clinical staging model for major depressive disorder.
Topics: Acute Disease; Adult; Antidepressive Agents; Citalopram; Cyclohexanols; Depression; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Paroxetine; Recurrence; Thiophenes; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2013 |
Sexual side effects of serotonergic antidepressants: mediated by inhibition of serotonin on central dopamine release?
Topics: Animals; Antidepressive Agents; Aza Compounds; Brain; Bridged Bicyclo Compounds, Heterocyclic; Bupropion; Buspirone; Cyclohexanols; Disease Models, Animal; Dopamine; Female; Humans; Indoles; Male; Norepinephrine; Paroxetine; Pyridines; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Serotonin; Sexual Behavior, Animal; Sexual Dysfunction, Physiological; Synaptic Transmission; Venlafaxine Hydrochloride | 2014 |
Update on the efficacy of pharmacotherapy for social anxiety disorder: a meta-analysis.
Topics: Antidepressive Agents; Antipsychotic Agents; Cyclohexanols; Humans; Monoamine Oxidase Inhibitors; Paroxetine; Phenelzine; Phobic Disorders; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2014 |
Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults.
Topics: Adrenergic Uptake Inhibitors; Adult; Citalopram; Cyclohexanols; Fluoxetine; Fluvoxamine; Humans; Norepinephrine; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Tension-Type Headache; Venlafaxine Hydrochloride | 2015 |
56 trial(s) available for paroxetine and cyclohexanol
| Article | Year |
|---|---|
Differential pharmacological treatment response in high angry hostile and low angry hostile depressed patients: a retrospective analysis.
Topics: 1-Naphthylamine; Adult; Ambulatory Care; Analysis of Variance; Anger; Cyclohexanols; Depressive Disorder; Desipramine; Female; Hostility; Humans; Male; Paroxetine; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 1997 |
Comparison of the effects of venlafaxine, paroxetine and desipramine on the pupillary light reflex in man.
Topics: Adrenergic Uptake Inhibitors; Adult; Cross-Over Studies; Cyclohexanols; Desipramine; Double-Blind Method; Humans; Male; Paroxetine; Reflex, Pupillary; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 1999 |
[The concept of resistant depression and therapeutic strategies, particularly, with venlafaxine].
Topics: Antidepressive Agents, Second-Generation; Chronic Disease; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Drug Resistance; Humans; Paroxetine; Remission, Spontaneous; Severity of Illness Index; Venlafaxine Hydrochloride | 1999 |
Comparison of the effects of venlafaxine, desipramine, and paroxetine on noradrenaline- and methoxamine-evoked constriction of the dorsal hand vein.
Topics: Adrenergic alpha-Agonists; Adult; Blood Pressure; Cross-Over Studies; Cyclohexanols; Desipramine; Double-Blind Method; Drug Interactions; Hand; Heart Rate; Humans; Male; Methoxamine; Norepinephrine; Paroxetine; Salivation; Selective Serotonin Reuptake Inhibitors; Vasoconstriction; Veins; Venlafaxine Hydrochloride | 1999 |
Acute effects of venlafaxine and paroxetine on serotonergic transmission in human volunteers.
Topics: Adolescent; Adult; Area Under Curve; Clomipramine; Cyclohexanols; Human Growth Hormone; Humans; Male; Nausea; Paroxetine; Prolactin; Selective Serotonin Reuptake Inhibitors; Serotonin; Synaptic Transmission; Tryptophan; Venlafaxine Hydrochloride; Vomiting | 1999 |
Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison.
Topics: Adult; Antidepressive Agents; Cyclohexanols; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Female; Humans; Male; Middle Aged; Paroxetine; Treatment Outcome; Venlafaxine Hydrochloride | 1999 |
CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations.
Topics: Chromatography, High Pressure Liquid; Cross-Over Studies; Cyclohexanols; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Dextromethorphan; Dextrorphan; Fluoxetine; Humans; Isoenzymes; Paroxetine; Phenotype; Selective Serotonin Reuptake Inhibitors; Sertraline; Venlafaxine Hydrochloride | 2000 |
Lymphocyte proliferation among major depressive and dysthymic patients with typical or atypical features.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Dysthymic Disorder; Female; Fluoxetine; Humans; Immune Tolerance; Lymphocyte Activation; Male; Middle Aged; Paroxetine; Personality Inventory; Sertraline; Venlafaxine Hydrochloride | 2000 |
The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder; Double-Blind Method; Dysthymic Disorder; Female; Humans; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Venlafaxine Hydrochloride | 2000 |
Sertraline, paroxetine, and venlafaxine in refugee posttraumatic stress disorder with depression symptoms.
Topics: Adult; Cyclohexanols; Depression; Female; Humans; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Refugees; Selective Serotonin Reuptake Inhibitors; Sertraline; Severity of Illness Index; Stress Disorders, Post-Traumatic; Surveys and Questionnaires; Treatment Outcome; Venlafaxine Hydrochloride | 2001 |
Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Cytochrome P-450 CYP2D6; Dopamine Uptake Inhibitors; Drug Interactions; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sexual Behavior; Surveys and Questionnaires; Treatment Outcome; Venlafaxine Hydrochloride | 2002 |
A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers.
Topics: Anticonvulsants; Antidepressive Agents, Second-Generation; Bipolar Disorder; Cyclohexanols; Drug Therapy, Combination; Female; Humans; Lithium; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Single-Blind Method; Treatment Outcome; Venlafaxine Hydrochloride | 2002 |
Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study.
Topics: Adult; Aged; Ambulatory Care; Antipsychotic Agents; Cyclohexanols; Dibenzothiazepines; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Paroxetine; Psychiatric Status Rating Scales; Quetiapine Fumarate; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2002 |
Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health.
Topics: Adult; Buspirone; Colon; Cyclohexanols; Double-Blind Method; Fasting; Female; Gastric Emptying; Gastrointestinal Motility; Humans; Male; Middle Aged; Paroxetine; Postprandial Period; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Tomography, Emission-Computed, Single-Photon; Venlafaxine Hydrochloride | 2003 |
Effect of a pharmacological intervention on quality of life in patients with obsessive-compulsive disorder.
Topics: Adult; Cyclohexanols; Double-Blind Method; Female; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Paroxetine; Quality of Life; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Social Behavior; Venlafaxine Hydrochloride | 2003 |
A score for predicting response to pharmacotherapy in obsessive-compulsive disorder.
Topics: Adolescent; Aged; Antidepressive Agents, Second-Generation; Cyclohexanols; Dose-Response Relationship, Drug; Double-Blind Method; Factor Analysis, Statistical; Female; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Paroxetine; Predictive Value of Tests; Psychiatric Status Rating Scales; Venlafaxine Hydrochloride | 2003 |
A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder.
Topics: Adolescent; Adult; Aged; Cyclohexanols; Desvenlafaxine Succinate; Double-Blind Method; Female; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Paroxetine; Patient Dropouts; Psychological Tests; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2003 |
A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder.
Topics: Administration, Oral; Adult; Antidepressive Agents, Second-Generation; Cross-Over Studies; Cyclohexanols; Double-Blind Method; Drug Resistance; Female; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Paroxetine; Severity of Illness Index; Treatment Outcome; Venlafaxine Hydrochloride | 2004 |
Comparison study of venlafaxine and paroxetine for the treatment of depression in elderly Chinese inpatients.
Topics: Aged; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Female; Hospitalization; Humans; Male; Paroxetine; Treatment Outcome; Venlafaxine Hydrochloride | 2004 |
Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Anxiety Disorders; Control Groups; Cyclohexanols; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Evaluation; Female; Follow-Up Studies; Humans; Male; Middle Aged; Paroxetine; Phobic Disorders; Psychiatric Status Rating Scales; Treatment Outcome; Venlafaxine Hydrochloride | 2004 |
Geriatric depression treatment in nonresponders to selective serotonin reuptake inhibitors.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Combined Modality Therapy; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Drug Therapy, Combination; Female; Geriatric Assessment; Humans; Lithium; Male; Nortriptyline; Paroxetine; Psychiatric Status Rating Scales; Psychotherapy; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2004 |
Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder.
Topics: Adult; Cyclohexanols; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Nausea; Paroxetine; Phobic Disorders; Placebos; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Venlafaxine Hydrochloride | 2005 |
Efficacy screening trials of paroxetine, pentoxifylline, riluzole, pramipexole and venlafaxine in cocaine dependence.
Topics: Adolescent; Adult; Antidepressive Agents; Benzothiazoles; Cocaine-Related Disorders; Cyclohexanols; Dopamine Agonists; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Paroxetine; Pentoxifylline; Phosphodiesterase Inhibitors; Pramipexole; Riluzole; Selective Serotonin Reuptake Inhibitors; Thiazoles; Venlafaxine Hydrochloride | 2005 |
Do venlafaxine XR and paroxetine equally influence negative and positive affect?
Topics: Adult; Affect; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Paroxetine; Personality Assessment; Regression Analysis; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2005 |
Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo.
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Fluoxetine; Humans; Paroxetine; Placebos; Treatment Outcome; Venlafaxine Hydrochloride | 2005 |
Effects of paroxetine and venlafaxine XR on heart rate variability in depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder; Double-Blind Method; Female; Heart Rate; Humans; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Venlafaxine Hydrochloride | 2005 |
Behavior therapy augments response of patients with obsessive-compulsive disorder responding to drug treatment.
Topics: Adult; Ambulatory Care; Behavior Therapy; Combined Modality Therapy; Cyclohexanols; Female; Humans; Male; Obsessive-Compulsive Disorder; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2005 |
Effects of paroxetine and venlafaxine on immune parameters in patients with obsessive compulsive disorder.
Topics: Adult; Cyclohexanols; Cytokines; Double-Blind Method; Female; Humans; Killer Cells, Natural; Male; Middle Aged; Obsessive-Compulsive Disorder; Paroxetine; Selective Serotonin Reuptake Inhibitors; Statistics, Nonparametric; Tumor Necrosis Factor-alpha; Venlafaxine Hydrochloride | 2006 |
Antidepressant treatment outcomes of psychogenic movement disorder.
Topics: Adult; Ambulatory Care; Anxiety Disorders; Chronic Disease; Citalopram; Combined Modality Therapy; Comorbidity; Conversion Disorder; Cyclohexanols; Depressive Disorder; Diagnostic and Statistical Manual of Mental Disorders; Female; Humans; Hypochondriasis; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Psychotherapy; Selective Serotonin Reuptake Inhibitors; Somatoform Disorders; Treatment Outcome; Venlafaxine Hydrochloride | 2005 |
Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteers.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Blood Platelets; Blood Pressure; Cyclohexanols; Desipramine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Paroxetine; Piperazines; Reference Values; Reproducibility of Results; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Time Factors; Triazoles; Tyramine; Venlafaxine Hydrochloride | 2007 |
Comparison of venlafaxine extended release versus paroxetine for treatment of patients with generalized anxiety disorder.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cyclohexanols; Delayed-Action Preparations; Drug Administration Schedule; Female; Headache; Humans; Male; Middle Aged; Nausea; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sweating; Venlafaxine Hydrochloride; Weight Gain | 2006 |
The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Female; Fluoxetine; Humans; Interleukin-12; Male; Middle Aged; Paroxetine; Time Factors; Transforming Growth Factor beta; Transforming Growth Factor beta1; Treatment Outcome; Venlafaxine Hydrochloride | 2006 |
A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
Topics: Adult; Agoraphobia; Antidepressive Agents, Second-Generation; Cyclohexanols; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Panic Disorder; Paroxetine; Personality Inventory; Psychometrics; Quality of Life; Treatment Outcome; Venlafaxine Hydrochloride | 2007 |
Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial.
Topics: Adult; Cyclohexanols; Double-Blind Method; Female; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Paroxetine; Polymorphism, Genetic; Receptor, Serotonin, 5-HT1B; Receptor, Serotonin, 5-HT2A; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2007 |
A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder.
Topics: Abortion, Spontaneous; Administration, Oral; Adult; Affective Disorders, Psychotic; Cyclohexanols; Delayed-Action Preparations; Diagnostic and Statistical Manual of Mental Disorders; Diarrhea; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Outpatients; Panic Disorder; Paroxetine; Pregnancy; Pregnancy, Unplanned; Remission Induction; Selective Serotonin Reuptake Inhibitors; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2007 |
Venlafaxine vs. paroxetine in the acute phase of treatment for major depressive disorder among Han Chinese population in Taiwan.
Topics: Acute Disease; Adult; Asian People; China; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Paroxetine; Pharmacogenetics; Prospective Studies; Psychiatric Status Rating Scales; Remission Induction; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2007 |
A randomized, single-blind, comparison of venlafaxine with paroxetine in elderly patients suffering from resistant depression.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Cyclohexanols; Depression; Diagnostic and Statistical Manual of Mental Disorders; Dizziness; Dose-Response Relationship, Drug; Drug Resistance; Female; Humans; Male; Nausea; Paroxetine; Psychiatric Status Rating Scales; Remission Induction; Selective Serotonin Reuptake Inhibitors; Single-Blind Method; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride; Xerostomia | 2007 |
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depressive Disorder, Major; Drug Resistance; Female; Fluoxetine; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2008 |
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Aripiprazole; Citalopram; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Fatigue; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Sertraline; Single-Blind Method; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride; Weight Gain; Withholding Treatment | 2008 |
Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Brain; Brain Chemistry; Cyclohexanols; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Nordefrin; Norepinephrine Plasma Membrane Transport Proteins; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Time Factors; Venlafaxine Hydrochloride; Young Adult | 2008 |
Plasma brain-derived neurotrophic factor as a peripheral marker for the action mechanism of antidepressants.
Topics: Adult; Antidepressive Agents; Biomarkers; Brain-Derived Neurotrophic Factor; Case-Control Studies; Chi-Square Distribution; Citalopram; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Male; Matched-Pair Analysis; Neuropsychological Tests; Paroxetine; Reference Values; Severity of Illness Index; Treatment Outcome; Venlafaxine Hydrochloride | 2008 |
The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults.
Topics: Adult; Antidepressive Agents; Area Under Curve; Cross-Over Studies; Cyclohexanols; Cytochrome P-450 CYP2D6 Inhibitors; Desipramine; Desvenlafaxine Succinate; Drug Interactions; Enzyme Inhibitors; Female; Genotype; Humans; Least-Squares Analysis; Male; Middle Aged; Paroxetine; United States; Young Adult | 2009 |
Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents: predictors and moderators of treatment response.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Chronic Disease; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depressive Disorder; Drug Resistance; Female; Fluoxetine; Humans; Male; Paroxetine; Personality Inventory; Prognosis; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2009 |
Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study.
Topics: Adolescent; Antidepressive Agents; Benzodiazepines; Citalopram; Cognitive Behavioral Therapy; Cross-Sectional Studies; Cyclohexanols; Depressive Disorder, Major; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Self-Injurious Behavior; Suicide; Suicide, Attempted; Venlafaxine Hydrochloride | 2009 |
Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; China; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Drug Resistance; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Pilot Projects; Psychiatric Status Rating Scales; Remission Induction; Treatment Outcome; Venlafaxine Hydrochloride | 2010 |
Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials.
Topics: Adult; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Neurotransmitter Uptake Inhibitors; Paroxetine; Placebos; Tropanes; Venlafaxine Hydrochloride | 2012 |
Adjunctive sleep medications and depression outcome in the treatment of serotonin-selective reuptake inhibitor resistant depression in adolescents study.
Topics: Adolescent; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Cytochrome P-450 CYP2D6 Inhibitors; Depressive Disorder, Major; Drug Interactions; Drug Resistance; Female; Fluoxetine; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Self-Injurious Behavior; Sleep Wake Disorders; Trazodone; Treatment Outcome; Venlafaxine Hydrochloride | 2012 |
Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Anxiety Disorders; Citalopram; Cyclohexanols; Double-Blind Method; Drug Therapy, Combination; Europe; Female; gamma-Aminobutyric Acid; Humans; Kaplan-Meier Estimate; Least-Squares Analysis; Linear Models; Male; Middle Aged; Odds Ratio; Paroxetine; Placebos; Pregabalin; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Time Factors; Treatment Outcome; United States; Venlafaxine Hydrochloride | 2012 |
A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Parkinson Disease; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Venlafaxine Hydrochloride | 2012 |
Leptin plasma concentrations increase during antidepressant treatment with amitriptyline and mirtazapine, but not paroxetine and venlafaxine: leptin resistance mediated by antihistaminergic activity?
Topics: Adult; Aged; Aged, 80 and over; Amitriptyline; Analysis of Variance; Antidepressive Agents; Biomarkers; Body Mass Index; Cyclohexanols; Depression; Female; Humans; Leptin; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Time Factors; Treatment Outcome; Up-Regulation; Venlafaxine Hydrochloride; Weight Gain; Young Adult | 2013 |
[Effects of apolipoprotein E genetic polymorphism on susceptibility of depression and efficacy of antidepressants].
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Apolipoproteins E; Cyclohexanols; Depression; Female; Genetic Predisposition to Disease; Humans; Male; Middle Aged; Paroxetine; Polymorphism, Genetic; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2012 |
Difference in remission in a Chinese population with anxious versus nonanxious treatment-resistant depression: a report of OPERATION study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety Disorders; Buspirone; China; Comorbidity; Cyclohexanols; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Remission Induction; Risperidone; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2013 |
Impact of treatments for depression on comorbid anxiety, attentional, and behavioral symptoms in adolescents with selective serotonin reuptake inhibitor-resistant depression.
Topics: Adolescent; Anxiety; Attention Deficit and Disruptive Behavior Disorders; Behavioral Symptoms; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Cyclohexanols; Depressive Disorder, Treatment-Resistant; Fluoxetine; Humans; Paroxetine; Remission Induction; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome; Venlafaxine Hydrochloride | 2013 |
The bidirectional relationship between body mass index and treatment outcome in adolescents with treatment-resistant depression.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Body Mass Index; Child; Citalopram; Cyclohexanols; Depressive Disorder, Treatment-Resistant; Female; Fluoxetine; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2013 |
How to switch to agomelatine after an unsuccessful try with paroxetine or venlafaxine.
Topics: Acetamides; Adult; Aged; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Drug Substitution; Female; Humans; Male; Middle Aged; Paroxetine; Venlafaxine Hydrochloride | 2015 |
Venlafaxine, paroxetine and milnacipran for major depressive disorder: a pragmatic 24-week study.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Cyclopropanes; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Milnacipran; Paroxetine; Remission Induction; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2014 |
91 other study(ies) available for paroxetine and cyclohexanol
| Article | Year |
|---|---|
Presynaptic Ca2+/calmodulin-dependent protein kinase II: autophosphorylation and activity increase in the hippocampus after long-term blockade of serotonin reuptake.
Topics: Amino Acid Sequence; Animals; Antidepressive Agents, Second-Generation; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Calcium-Calmodulin-Dependent Protein Kinases; Cerebral Cortex; Cyclohexanols; Cytosol; Fluvoxamine; Hippocampus; Male; Molecular Sequence Data; Neurotransmitter Uptake Inhibitors; Norepinephrine; Paroxetine; Phosphorylation; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Synaptic Vesicles; Synaptosomes; Time Factors; Venlafaxine Hydrochloride | 1995 |
Serotonin reuptake inhibitors in Raynaud's phenomenon.
Topics: 1-Naphthylamine; Adult; Aged; Cyclohexanols; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Raynaud Disease; Selective Serotonin Reuptake Inhibitors; Sertraline; Venlafaxine Hydrochloride | 1995 |
Drug craving and other negative reactions after abrupt substitution of nefazodone for other serotonergic agents.
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Drug Administration Schedule; Female; Fluoxetine; Humans; Male; Paroxetine; Piperazines; Recurrence; Serotonin Agents; Substance-Related Disorders; Triazoles; Venlafaxine Hydrochloride | 1996 |
Inhibition of 5-HT cell firing in the DRN by non-selective 5-HT reuptake inhibitors: studies on the role of 5-HT1A autoreceptors and noradrenergic mechanisms.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Action Potentials; Amitriptyline; Animals; Clomipramine; Cyclohexanols; Male; Neurons; Paroxetine; Piperazines; Pyridines; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Venlafaxine Hydrochloride | 1997 |
Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
Topics: 1-Naphthylamine; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liquid; Cyclohexanols; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Desipramine; Fluoxetine; Fluvoxamine; Frozen Sections; Humans; Hydroxylation; Imipramine; In Vitro Techniques; Lethal Dose 50; Microsomes, Liver; Mixed Function Oxygenases; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases; Venlafaxine Hydrochloride | 1997 |
Syndrome of inappropriate ADH secretion attributed to the serotonin re-uptake inhibitors, venlafaxine and paroxetine.
Topics: Aged; Aged, 80 and over; Cyclohexanols; Female; Humans; Inappropriate ADH Syndrome; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 1997 |
Breast enlargement during chronic antidepressant therapy.
Topics: Breast; Breast Diseases; Cyclohexanols; Depressive Disorder; Female; Fluoxetine; Humans; Hyperplasia; Male; Menopause; Paroxetine; Prolactin; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride; Weight Gain | 1997 |
Simultaneous measurement of venlafaxine and its major metabolite, oxydesmethylvenlafaxine, in human plasma by high-performance liquid chromatography with coulometric detection and utilisation of solid-phase extraction.
Topics: Administration, Oral; Chromatography, High Pressure Liquid; Cyclohexanols; Desvenlafaxine Succinate; Humans; Paroxetine; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Venlafaxine Hydrochloride | 1998 |
Blockade of 5-hydroxytryptamine and noradrenaline uptake by venlafaxine: a comparative study with paroxetine and desipramine.
Topics: Adrenergic Uptake Inhibitors; Animals; Cyclohexanols; Depression; Desipramine; Hippocampus; Injections, Intravenous; Iontophoresis; Male; Norepinephrine; Paroxetine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin; Venlafaxine Hydrochloride | 1998 |
Discrepancies between the in vitro and in vivo 5-HT and norepinephrine re-uptake blocking properties of venlafaxine.
Topics: Animals; Brain; Cyclohexanols; Desipramine; In Vitro Techniques; Neurons; Norepinephrine; Paroxetine; Raphe Nuclei; Rats; Selective Serotonin Reuptake Inhibitors; Serotonin; Synapses; Venlafaxine Hydrochloride | 1998 |
Evaluating the tolerability of the newer antidepressants.
Topics: Antidepressive Agents; Bupropion; Central Nervous System Diseases; Citalopram; Cyclohexanols; Delayed-Action Preparations; Drug Information Services; Fluvoxamine; Gastrointestinal Diseases; Guidelines as Topic; Humans; Incidence; Paroxetine; Piperazines; Placebos; Selective Serotonin Reuptake Inhibitors; Sertraline; Sexual Dysfunctions, Psychological; Triazoles; United States; United States Agency for Healthcare Research and Quality; Venlafaxine Hydrochloride | 1999 |
Venlafaxine: discrepancy between in vivo 5-HT and NE reuptake blockade and affinity for reuptake sites.
Topics: Action Potentials; Adrenergic Uptake Inhibitors; Animals; Binding Sites; Cyclohexanols; Desipramine; Fenfluramine; Hippocampus; In Vitro Techniques; Locus Coeruleus; Male; Neurons; Norepinephrine; Paroxetine; Piperazines; Piperoxan; Pyridines; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin; Tyramine; Venlafaxine Hydrochloride | 1999 |
[Proofs of efficacy].
Topics: Antidepressive Agents, Tricyclic; Clomipramine; Cyclohexanols; Depressive Disorder; Dose-Response Relationship, Drug; Fluoxetine; Humans; Norepinephrine; Paroxetine; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 1999 |
Differential effect of chronic antidepressant treatments on lipopolysaccharide-induced depressive-like behavioural symptoms in the rat.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Behavior, Animal; Body Weight; Cyclohexanols; Desipramine; Drinking Behavior; Eating; Endotoxins; Escherichia coli; Interleukin-10; Lipopolysaccharides; Male; Motor Activity; Paroxetine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Tumor Necrosis Factor-alpha; Venlafaxine Hydrochloride | 1999 |
Effect of subchronic antidepressant treatments on behavioral, neurochemical, and endocrine changes in the forced-swim test.
Topics: Amygdala; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Behavior, Animal; Biogenic Amines; Brain Chemistry; Cerebral Cortex; Corticosterone; Cyclohexanols; Depressive Disorder; Desipramine; Hormones; Hypothalamo-Hypophyseal System; Male; Motor Activity; Paroxetine; Rats; Rats, Sprague-Dawley; Serotonin; Swimming; Venlafaxine Hydrochloride | 2000 |
Drug therapy in treatment-resistant depression.
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 1999 |
Venlafaxine and paroxetine in treatment-resistant depression.
Topics: Cyclohexanols; Depression; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 1999 |
Newer antidepressants: a comparison of tolerability in general practice.
Topics: Adult; Aged; Antidepressive Agents; Cohort Studies; Cyclohexanols; Depressive Disorder; Family Practice; Female; Fluoxetine; Humans; Male; Middle Aged; Moclobemide; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Sertraline; Triazoles; Venlafaxine Hydrochloride | 1999 |
Drug treatment for resistant depression.
Topics: Bias; Cyclohexanols; Drug Resistance; Humans; Mental Disorders; Paroxetine; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2000 |
Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine.
Topics: Adult; Cyclohexanols; Depressive Disorder; Female; Humans; Libido; Male; Middle Aged; Moclobemide; Monoamine Oxidase Inhibitors; Ontario; Orgasm; Paroxetine; Prevalence; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sertraline; Sex Factors; Sexual Dysfunctions, Psychological; Treatment Outcome; Venlafaxine Hydrochloride | 2000 |
A depressed myocardium.
Topics: Adult; Anti-Arrhythmia Agents; Cardiomyopathies; Chest Pain; Cyclohexanols; Electrocardiography; Heart; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Tachycardia, Sinus; Venlafaxine Hydrochloride; Ventricular Function, Left | 2000 |
Potentiation by (-)Pindolol of the activation of postsynaptic 5-HT(1A) receptors induced by venlafaxine.
Topics: 5,7-Dihydroxytryptamine; Adrenergic beta-Antagonists; Animals; Cyclohexanols; Drug Synergism; Electrophysiology; Extracellular Space; Hippocampus; Injections, Intravenous; Male; Paroxetine; Pindolol; Piperazines; Pyramidal Cells; Pyridines; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Receptors, Neurotransmitter; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Selective Serotonin Reuptake Inhibitors; Serotonin Agents; Serotonin Antagonists; Venlafaxine Hydrochloride | 2000 |
Do antidepressants affect motivation in conditioned place preference?
Topics: Adrenergic Uptake Inhibitors; Amitriptyline; Animals; Antidepressive Agents; Behavior, Animal; Cocaine; Conditioning, Psychological; Cyclobutanes; Cyclohexanols; Dose-Response Relationship, Drug; Fluoxetine; Male; Motivation; Norepinephrine; Paroxetine; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Sertraline; Venlafaxine Hydrochloride | 2000 |
Serotonergic antidepressants and urinary incontinence.
Topics: Adult; Bipolar Disorder; Cyclohexanols; Depressive Disorder; Female; Humans; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Urinary Incontinence; Venlafaxine Hydrochloride | 2000 |
Breast cancer and hot flashes. Options for relief.
Topics: Breast Neoplasms; Cyclohexanols; Female; Hot Flashes; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2001 |
Prefrontal changes and treatment response prediction in depression.
Topics: Adult; Antidepressive Agents; Cyclohexanols; Depression; Depressive Disorder, Major; Electroencephalography; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Prefrontal Cortex; Sertraline; Venlafaxine Hydrochloride | 2001 |
Antidepressant discontinuation (withdrawal) symptoms presenting as 'stroke'.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Cyclohexanols; Diagnosis, Differential; Dysthymic Disorder; Female; Humans; Paroxetine; Stroke; Substance Withdrawal Syndrome; Venlafaxine Hydrochloride | 2001 |
Sertralilne, paroxetine and venlafaxine in refugee post traumatic stress disorder with depression symptoms.
Topics: Adult; Antidepressive Agents; Bosnia and Herzegovina; Cyclohexanols; Depressive Disorder; Female; Humans; Male; Middle Aged; Paroxetine; Pilot Projects; Refugees; Selective Serotonin Reuptake Inhibitors; Sertraline; Stress Disorders, Post-Traumatic; United States; Venlafaxine Hydrochloride; Warfare | 2001 |
Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Antidepressive Agents; Bupropion; Canada; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Moclobemide; Paroxetine; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 2002 |
Treatment of psychotic depression associated with steroid therapy in Churg-Strauss syndrome.
Topics: Adrenal Cortex Hormones; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Churg-Strauss Syndrome; Cyclohexanols; Depression; Electroconvulsive Therapy; Female; Humans; Middle Aged; Paroxetine; Risperidone; Venlafaxine Hydrochloride | 2002 |
Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Cyclohexanols; Desipramine; Dose-Response Relationship, Drug; Drug Interactions; Extracellular Space; Fluoxetine; Male; Microdialysis; Norepinephrine; Paroxetine; Piperazines; Prefrontal Cortex; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Venlafaxine Hydrochloride | 2002 |
Effects of acute treatment with paroxetine, citalopram and venlafaxine in vivo on noradrenaline and serotonin outflow: a microdialysis study in Swiss mice.
Topics: Animals; Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Dose-Response Relationship, Drug; Frontal Lobe; Male; Mice; Microdialysis; Norepinephrine; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Time Factors; Venlafaxine Hydrochloride | 2003 |
Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption.
Topics: Animals; Antidepressive Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Brain; Chromatography, High Pressure Liquid; Cyclohexanols; Doxepin; Drug Resistance, Multiple; Gene Expression; Injections, Subcutaneous; Kidney; Liver; Male; Mianserin; Mice; Mice, Knockout; Mirtazapine; Paroxetine; Point Mutation; Spleen; Venlafaxine Hydrochloride | 2003 |
Antidepressant drug treatment induces Arc gene expression in the rat brain.
Topics: Animals; Antidepressive Agents; Brain; Chlorpromazine; Cyclohexanols; Cytoskeletal Proteins; Desipramine; Gene Expression; Male; Monoamine Oxidase Inhibitors; Nerve Tissue Proteins; Neuronal Plasticity; Paroxetine; Prosencephalon; Rats; Rats, Sprague-Dawley; RNA, Messenger; Selective Serotonin Reuptake Inhibitors; Synaptic Transmission; Tranylcypromine; Up-Regulation; Venlafaxine Hydrochloride | 2003 |
Should children take antidepressants?
Topics: Adolescent; Affect; Antidepressive Agents; Child; Cyclohexanols; Humans; Paroxetine; Suicide; Venlafaxine Hydrochloride | 2003 |
Mechanisms for the inhibition of genital vascular responses by antidepressants in a female rabbit model.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Arginine; Blood Vessels; Citalopram; Cyclohexanols; Drug Interactions; Duloxetine Hydrochloride; Female; Nitric Oxide; Norepinephrine; Paroxetine; Phentolamine; Rabbits; Regional Blood Flow; Selective Serotonin Reuptake Inhibitors; Serotonin; Thiophenes; Vagina; Vasodilation; Venlafaxine Hydrochloride | 2004 |
Suicidal ideas with paroxetine or venlafaxine.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Cyclohexanols; Depressive Disorder; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Suicide; Suicide, Attempted; United States | 2004 |
Are selective serotonin re-uptake inhibitors associated with an increased risk of self-harm by antidepressant overdose?
Topics: Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Citalopram; Cyclohexanols; Doxepin; Drug Overdose; Drug Prescriptions; Emergency Service, Hospital; Female; Fluoxetine; Humans; Imipramine; Information Services; Male; Mianserin; Mirtazapine; Paroxetine; Patient Admission; Patient Readmission; Poison Control Centers; Retrospective Studies; Risk Assessment; Scotland; Selective Serotonin Reuptake Inhibitors; Self-Injurious Behavior; Sertraline; Trazodone; Venlafaxine Hydrochloride | 2004 |
Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study.
Topics: Adult; Benzylamines; Carbon Radioisotopes; Carrier Proteins; Citalopram; Corpus Striatum; Cyclohexanols; Delayed-Action Preparations; Dose-Response Relationship, Drug; Female; Fluoxetine; Humans; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Tissue Proteins; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Sertraline; Tomography, Emission-Computed; Venlafaxine Hydrochloride | 2004 |
Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats.
Topics: Acute Disease; Amines; Amitriptyline; Animals; Conscious Sedation; Cyclohexanecarboxylic Acids; Cyclohexanols; Cyclopropanes; Disease Models, Animal; Drug Therapy, Combination; Duloxetine Hydrochloride; Fluoxetine; Formaldehyde; Gabapentin; gamma-Aminobutyric Acid; Male; Methyltyrosines; Milnacipran; Neuromuscular Junction; Norepinephrine; p-Chloroamphetamine; Pain; Paroxetine; Rats; Rats, Sprague-Dawley; Serotonin; Thiophenes; Venlafaxine Hydrochloride | 2004 |
Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder.
Topics: Activities of Daily Living; Acute Disease; Ambulatory Care; Cost-Benefit Analysis; Cyclohexanols; Decision Support Techniques; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Drug Costs; Female; Fluoxetine; Fluvoxamine; Humans; Male; Paroxetine; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2004 |
Drugs vs. talk therapy: 3,079 readers rate their care for depression and anxiety.
Topics: Antidepressive Agents; Anxiety; Anxiety Disorders; Bupropion; Citalopram; Cyclohexanols; Depression; Drug Therapy; Fluoxetine; Humans; Paroxetine; Patient Satisfaction; Primary Health Care; Psychiatry; Psychology; Psychotherapy; Selective Serotonin Reuptake Inhibitors; Sertraline; Social Work | 2004 |
Implication of 5-HT2 receptor subtypes in the mechanism of action of antidepressants in the four plates test.
Topics: Animals; Antidepressive Agents; Avoidance Learning; Cyclohexanols; Electroshock; Hypnotics and Sedatives; Male; Mice; Motor Activity; Paroxetine; Punishment; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2B; Receptor, Serotonin, 5-HT2C; Receptors, GABA-A; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Serotonin Receptor Agonists; Stimulation, Chemical; Venlafaxine Hydrochloride | 2005 |
Simultaneous determination of fluoxetine, citalopram, paroxetine, venlafaxine in plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI).
Topics: Antidepressive Agents, Tricyclic; Chromatography, High Pressure Liquid; Citalopram; Cyclohexanols; Depression; Female; Fluoxetine; Humans; Male; Paroxetine; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Venlafaxine Hydrochloride | 2005 |
The four-plates test-retest paradigm to discriminate anxiolytic effects.
Topics: Adrenergic Uptake Inhibitors; Amphetamines; Animals; Anti-Anxiety Agents; Anxiety; Atropine; Avoidance Learning; Behavior, Animal; Benzodiazepines; Cholinergic Agents; Cyclohexanols; Discrimination, Psychological; Dose-Response Relationship, Drug; Male; Mice; Paroxetine; Receptors, GABA-A; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT2 Receptor Agonists; Venlafaxine Hydrochloride | 2005 |
alpha2-Adrenergic agonists antagonise the anxiolytic-like effect of antidepressants in the four-plate test in mice.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Citalopram; Clonidine; Cyclohexanols; Cyclopropanes; Dose-Response Relationship, Drug; Drug Antagonism; Guanabenz; Male; Mice; Milnacipran; Motor Activity; Paroxetine; Punishment; Selective Serotonin Reuptake Inhibitors; Statistics, Nonparametric; Venlafaxine Hydrochloride | 2005 |
A comparison of the chronic treatment effects of venlafaxine and other antidepressants on serotonin and norepinephrine transporters.
Topics: Amitriptyline; Animals; Antidepressive Agents, Second-Generation; Brain; Cyclohexanols; Desipramine; Male; Norepinephrine Plasma Membrane Transport Proteins; Paroxetine; Radioligand Assay; Rats; Rats, Sprague-Dawley; Serotonin Plasma Membrane Transport Proteins; Venlafaxine Hydrochloride | 2006 |
An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Citalopram; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Female; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Sertraline; Thiophenes; Treatment Outcome; Venlafaxine Hydrochloride | 2005 |
[Cannabis dependence and social phobia].
Topics: Adult; Cyclohexanols; Drug Therapy, Combination; Humans; Male; Marijuana Abuse; Paroxetine; Phobic Disorders; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2005 |
Antidepressant withdrawal symptoms-telephone calls to a national medication helpline.
Topics: Antidepressive Agents; Cyclohexanols; Hotlines; Humans; Monoamine Oxidase Inhibitors; Paroxetine; Retrospective Studies; Substance Withdrawal Syndrome; Television; United Kingdom; Venlafaxine Hydrochloride | 2006 |
[Unipolar depression suddenly switches to hypomania in a patient who has just started taking venlafaxine].
Topics: Adult; Antidepressive Agents, Second-Generation; Bipolar Disorder; Cyclohexanols; Depressive Disorder; Drug Interactions; Drug Therapy, Combination; Female; Humans; Paroxetine; Treatment Outcome; Venlafaxine Hydrochloride | 2006 |
Quetiapine augmentation in lactation: a series of case reports.
Topics: Adult; Antipsychotic Agents; Cyclohexanols; Dibenzothiazepines; Female; Humans; Infant; Infant Behavior; Lactation; Milk, Human; Paroxetine; Quetiapine Fumarate; Risk Assessment; Venlafaxine Hydrochloride | 2006 |
Analgesic effects of serotonergic, noradrenergic or dual reuptake inhibitors in the carrageenan test in rats: evidence for synergism between serotonergic and noradrenergic reuptake inhibition.
Topics: Adrenergic Uptake Inhibitors; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain Chemistry; Carrageenan; Cyclohexanols; Desipramine; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Interactions; Duloxetine Hydrochloride; Edema; Fluoxetine; Hot Temperature; Hyperalgesia; Male; Norepinephrine; Paroxetine; Pressure; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin; Sertraline; Thiophenes; Venlafaxine Hydrochloride | 2006 |
Cytotoxicity of different selective serotonin reuptake inhibitors (SSRIs) against cancer cells.
Topics: Animals; Antidepressive Agents; Benzimidazoles; Biological Transport; Cell Line, Tumor; Cyclohexanols; Fibroblasts; Humans; Ions; Mice; Necrosis; Neoplasms; Paroxetine; Propidium; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2006 |
Antidepressant response in the elderly.
Topics: Adult; Age Factors; Aged; Antidepressive Agents; Anxiety Disorders; Bipolar Disorder; Cyclohexanols; Depressive Disorder, Major; Female; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Personality Inventory; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 2007 |
An abbreviated version of the Connor-Davidson Resilience Scale (CD-RISC), the CD-RISC2: psychometric properties and applications in psychopharmacological trials.
Topics: Antidepressive Agents; Anxiety Disorders; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder, Major; Fluoxetine; Humans; Kava; Mianserin; Mirtazapine; Paroxetine; Psychometrics; Sertraline; Stress Disorders, Post-Traumatic; Surveys and Questionnaires; Venlafaxine Hydrochloride | 2007 |
Antidepressant use and off-label prescribing in children and adolescents in Dutch general practice (2001-2005).
Topics: Adolescent; Adrenergic Uptake Inhibitors; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Child; Cyclohexanols; Depressive Disorder; Drug Labeling; Drug Prescriptions; Drug Utilization; Family Practice; Female; Humans; Imipramine; Male; Netherlands; Nocturnal Enuresis; Paroxetine; Practice Patterns, Physicians'; Selective Serotonin Reuptake Inhibitors; Tension-Type Headache; Time Factors; Venlafaxine Hydrochloride | 2007 |
Addition of cognitive-behavioral therapy for nonresponders to medication for obsessive-compulsive disorder: a naturalistic study.
Topics: Adult; Citalopram; Clomipramine; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Demography; Drug Resistance; Female; Fluoxetine; Fluvoxamine; Humans; Male; Obsessive-Compulsive Disorder; Paroxetine; Practice Guidelines as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 2007 |
Antidepressant-like effects of serotonin type-3 antagonist, ondansetron: an investigation in behaviour-based rodent models.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antidepressive Agents; Behavior, Animal; Cyclohexanols; Desipramine; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Exploratory Behavior; Fluoxetine; Hindlimb Suspension; Male; Maze Learning; Mice; Motor Activity; Olfactory Bulb; Ondansetron; Paroxetine; Rats; Rats, Wistar; Serotonin 5-HT3 Receptor Agonists; Serotonin 5-HT3 Receptor Antagonists; Stress, Psychological; Venlafaxine Hydrochloride | 2008 |
Similar discontinuation symptoms for withdrawal from medium-dose paroxetine and venlafaxine after nine years in the same patient.
Topics: Adult; Cyclohexanols; Female; Humans; Marijuana Smoking; Paroxetine; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome; Venlafaxine Hydrochloride | 2008 |
Do new-generation antidepressants work?
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Depression; Fluoxetine; Humans; Paroxetine; Piperazines; Treatment Outcome; Triazoles; Venlafaxine Hydrochloride | 2008 |
Flat dose-response curves for efficacy: what do they mean to the clinician?
Topics: Attitude of Health Personnel; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluoxetine; Humans; Neurotransmitter Uptake Inhibitors; Paroxetine; Physicians; Randomized Controlled Trials as Topic; Sertraline; Treatment Outcome; United States; United States Food and Drug Administration | 2008 |
Big interest in heavy drugs.
Topics: Clinical Trials, Phase I as Topic; Cyclohexanols; Deuterium; Drug Industry; Female; Humans; Paroxetine; Patents as Topic; Pharmaceutical Preparations; Venlafaxine Hydrochloride | 2009 |
Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus.
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Body Mass Index; Case-Control Studies; Cyclohexanols; Depressive Disorder; Diabetes Mellitus; Female; Fluvoxamine; Humans; Incidence; Male; Middle Aged; Paroxetine; Risk Factors; Selective Serotonin Reuptake Inhibitors; Time Factors; United Kingdom; Venlafaxine Hydrochloride | 2009 |
TORDIA: unique opportunity to explore half-life theory.
Topics: Adolescent; Antidepressive Agents; Cyclohexanols; Depressive Disorder; Drug Resistance; Half-Life; Humans; Paroxetine; Randomized Controlled Trials as Topic; Risk Factors; Selective Serotonin Reuptake Inhibitors; Self-Injurious Behavior; Suicide; Venlafaxine Hydrochloride | 2009 |
Brain creatine kinase activity is increased by chronic administration of paroxetine.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Brain; Corpus Striatum; Creatine Kinase, BB Form; Cyclohexanols; Hippocampus; Male; Nortriptyline; Paroxetine; Prefrontal Cortex; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2009 |
The treatment of SSRI-resistant depression in adolescents (TORDIA): in search of the best next step.
Topics: Adolescent; Antidepressive Agents; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Female; Fluoxetine; Humans; Male; Multicenter Studies as Topic; Paroxetine; Personality Assessment; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Suicide; Suicide Prevention; Suicide, Attempted; Venlafaxine Hydrochloride | 2009 |
Agomelatine: new drug. Adverse effects and no proven efficacy.
Topics: Acetamides; Animals; Antidepressive Agents; Bias; Carcinogens; Clinical Trials as Topic; Cyclohexanols; Depression; Depressive Disorder; Double-Blind Method; Drug Approval; Europe; Fluoxetine; Humans; Hypnotics and Sedatives; Melatonin; Paroxetine; Psychiatric Status Rating Scales; Receptors, Melatonin; Recurrence; Selective Serotonin Reuptake Inhibitors; Suicide; Treatment Outcome; Venlafaxine Hydrochloride | 2009 |
When is a "generic" medication not really a generic?
Topics: Bupropion; Cyclohexanols; Drug Costs; Drug Labeling; Drug Prescriptions; Drugs, Generic; Humans; Marketing of Health Services; Paroxetine; Patient Selection; Psychiatric Nursing; Psychotropic Drugs; Therapeutic Equivalency; United States; United States Food and Drug Administration; Valproic Acid; Venlafaxine Hydrochloride | 2010 |
Deaths involving serotonergic drugs.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Australia; Cause of Death; Citalopram; Cyclohexanols; Female; Fluoxetine; Forensic Toxicology; Gas Chromatography-Mass Spectrometry; Humans; Male; Middle Aged; N-Methyl-3,4-methylenedioxyamphetamine; Paroxetine; Serotonin Agents; Sertraline; Tramadol; Venlafaxine Hydrochloride | 2010 |
Selective serotonin reuptake inhibitors and the risk of cataracts: a nested case-control study.
Topics: Aged; Case-Control Studies; Cataract; Cataract Extraction; Cyclohexanols; Female; Fluvoxamine; Humans; Male; Paroxetine; Pharmacoepidemiology; Risk Factors; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2010 |
Evaluation of Krebs cycle enzymes in the brain of rats after chronic administration of antidepressants.
Topics: Animals; Antidepressive Agents; Brain; Citrate (si)-Synthase; Citric Acid Cycle; Cyclohexanols; Male; Nortriptyline; Paroxetine; Rats; Rats, Wistar; Succinate Dehydrogenase; Venlafaxine Hydrochloride | 2010 |
Use of antidepressants during pregnancy and the risk of spontaneous abortion.
Topics: Abortion, Spontaneous; Adolescent; Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Case-Control Studies; Confidence Intervals; Cyclohexanols; Depressive Disorder; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Gestational Age; Humans; Middle Aged; Odds Ratio; Paroxetine; Pregnancy; Pregnancy Complications; Quebec; Registries; Risk Factors; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride; Young Adult | 2010 |
A rapid, Web-based method for obtaining patient views on effects and side-effects of antidepressants.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Data Collection; Desvenlafaxine Succinate; Duloxetine Hydrochloride; Fatigue; Fluvoxamine; Humans; Internet; Lethargy; Mianserin; Mirtazapine; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Sleep Stages; Thiophenes; Venlafaxine Hydrochloride | 2011 |
Rapid HPLC method for the simultaneous monitoring of duloxetine, venlaflaxine, fluoxetine and paroxetine in biofluids.
Topics: Chromatography, High Pressure Liquid; Cyclohexanols; Duloxetine Hydrochloride; Fluoxetine; Humans; Limit of Detection; Paroxetine; Reproducibility of Results; Selective Serotonin Reuptake Inhibitors; Sensitivity and Specificity; Thiophenes; Venlafaxine Hydrochloride | 2009 |
Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clomipramine; Cyclohexanols; Depressive Disorder; Female; Genetic Association Studies; Humans; Male; Middle Aged; Paroxetine; Piperazines; Polymorphism, Single Nucleotide; Receptor, Serotonin, 5-HT1B; Severity of Illness Index; Suicidal Ideation; Tacrolimus Binding Proteins; Triazoles; Venlafaxine Hydrochloride; Young Adult | 2011 |
Balance control improves following replacement of paroxetine with venlafaxine and levodopa in a case of microvascular dementia.
Topics: Aged, 80 and over; Antidepressive Agents, Second-Generation; Antiparkinson Agents; Cyclohexanols; Dementia, Vascular; Diagnosis, Computer-Assisted; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Microvessels; Paroxetine; Postural Balance; Venlafaxine Hydrochloride | 2011 |
Antidepressant use during pregnancy. FPIN’s clinical inquiries.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Citalopram; Cyclohexanols; Evidence-Based Medicine; Female; Fluoxetine; Humans; Odds Ratio; Paroxetine; Physicians, Family; Pregnancy; Pregnancy Complications; Risk Assessment; Selective Serotonin Reuptake Inhibitors; Sertraline; Venlafaxine Hydrochloride | 2011 |
Venlafaxine in somatopsychic and autopsychic depersonalization.
Topics: Agoraphobia; Cyclohexanols; Depersonalization; Depressive Disorder; Humans; Male; Obsessive Behavior; Panic Disorder; Paroxetine; Retreatment; Selective Serotonin Reuptake Inhibitors; Trimipramine; Venlafaxine Hydrochloride; Young Adult | 2011 |
[Approximate entropy of the placebo effect in clinical trials of newer antidepressants].
Topics: Antidepressive Agents, Second-Generation; Clinical Trials as Topic; Cyclohexanols; Depression; Fluoxetine; Humans; Paroxetine; Placebo Effect; Placebos; Severity of Illness Index; Venlafaxine Hydrochloride | 2010 |
Time to discontinuation among the three second-generation antidepressants in a naturalistic outpatient setting of depression.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder; Female; Humans; Korea; Male; Medication Adherence; Mianserin; Middle Aged; Mirtazapine; Outpatients; Paroxetine; Retrospective Studies; Venlafaxine Hydrochloride | 2011 |
High venlafaxine serum levels after prior fluoxetine medication.
Topics: Antidepressive Agents, Second-Generation; Cholinergic Antagonists; Cyclohexanols; Cytochrome P-450 CYP2D6 Inhibitors; Depressive Disorder; Female; Fluoxetine; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2012 |
Glad about SAD (PD).
Topics: Antidepressive Agents; Cyclohexanols; Depressive Disorder; Female; Humans; Male; Parkinson Disease; Paroxetine; Venlafaxine Hydrochloride | 2012 |
A simple HPLC method for the simultaneous determination of two selective serotonin reuptake inhibitors and two serotonin-norepinephrine reuptake inhibitors in hair, nail clippings, and cerebrospinal fluid.
Topics: Adrenergic Uptake Inhibitors; Biological Transport; Cerebrospinal Fluid; Chromatography, High Pressure Liquid; Cyclohexanols; Duloxetine Hydrochloride; Fluoxetine; Hair; Humans; Nails; Norepinephrine; Paroxetine; Selective Serotonin Reuptake Inhibitors; Thiophenes; Venlafaxine Hydrochloride | 2012 |
Antidepressants inhibit DNA methyltransferase 1 through reducing G9a levels.
Topics: Animals; Antidepressive Agents; Astrocytes; Carbamazepine; Cells, Cultured; Cerebral Cortex; Citalopram; Cyclohexanols; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enzyme Inhibitors; Glycolipids; Histone-Lysine N-Methyltransferase; Imipramine; Indoles; Maleimides; Mice; Nerve Tissue Proteins; Neural Stem Cells; Neurons; Paroxetine; Protein Interaction Mapping; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Venlafaxine Hydrochloride | 2012 |
Investigating the roles of different monoamine transmitters and impulse control using the 5-choice serial reaction time task.
Topics: Acetamides; Adrenergic alpha-2 Receptor Antagonists; Animals; Antidepressive Agents; Behavior, Animal; Bupropion; Choice Behavior; Cyclobutanes; Cyclohexanols; Fluoxetine; Hypnotics and Sedatives; Idazoxan; Impulsive Behavior; Male; Norepinephrine; Paroxetine; Rats; Reaction Time; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2013 |
Different serum BDNF levels in depression: results from BDNF studies in FYR Macedonia and Bulgaria.
Topics: Adult; Aged; Brain-Derived Neurotrophic Factor; Bulgaria; Cyclohexanols; Depressive Disorder; Female; Humans; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Republic of North Macedonia; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2013 |
[Taperingstrips for paroxetine and venlafaxine].
Topics: Antidepressive Agents; Cyclohexanols; Depressive Disorder; Dose-Response Relationship, Drug; Feasibility Studies; Humans; Paroxetine; Substance Withdrawal Syndrome; Venlafaxine Hydrochloride | 2013 |
Lack of influence of rs4680 (COMT) and rs6276 (DRD2) on diagnosis and clinical outcomes in patients with major depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Catechol O-Methyltransferase; Cyclohexanols; Depressive Disorder, Major; Epistasis, Genetic; Female; Humans; Male; Middle Aged; Paroxetine; Receptors, Dopamine D2; Republic of Korea; Treatment Outcome; Venlafaxine Hydrochloride | 2014 |
Severity of depression and anxiety are predictors of response to antidepressant treatment in Parkinson's disease.
Topics: Aged; Antidepressive Agents; Anxiety; Cyclohexanols; Datasets as Topic; Depression; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Parkinson Disease; Paroxetine; Predictive Value of Tests; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Severity of Illness Index; Venlafaxine Hydrochloride | 2014 |
Differential Potency of Venlafaxine, Paroxetine, and Atomoxetine to Inhibit Serotonin and Norepinephrine Reuptake in Patients With Major Depressive Disorder.
Topics: Antidepressive Agents, Second-Generation; Atomoxetine Hydrochloride; Cyclohexanols; Depressive Disorder, Major; Humans; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Tyramine; Venlafaxine Hydrochloride | 2022 |